medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252741; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Ilies Benotmane^{1,2} MD, Gabriela Gautier -Vargas¹ MD, Noelle Cognard¹ MD, Jerome

Olagne¹ MD, Francoise Heibel¹ MD, Laura Braun-Parvez¹ MD, Jonas Martzloff¹ MD, Peggy

Perrin¹ MD, Bruno Moulin^{1,2} MD, PhD, Samira Fafi-Kremer^{2,3} MD, PhD, Sophie Caillard^{1,2}

MD, PhD

¹Department of Nephrology and Transplantation, University Hospital, Strasbourg, France ²Fédération de Médecine Translationnelle (FMTS), Strasbourg, France ³Department of virology, University Hospital, Strasbourg, France

Corresponding author: Ilies Benotmane, Department of Nephrology and Transplantation, Strasbourg University Hospital, 1 Place de l'Hopital, 67091 Strasbourg, Cedex, France. E-mail address: <u>Ilies.benotmane@chru-strasbourg.fr</u>

Keyword: kidney transplant recipient, COVID-19 vaccine

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252741; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252741; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

International recommendations on COVID-19 vaccine distribution have given priority to immunocompromised patients – including kidney transplant recipients (KTRs).^{1,2} Unfortunately, this guidance has been released without inclusion of this clinical population in vaccine clinical trials. In an effort to shed light on the efficacy and safety of an mRNA COVID-19 vaccine in KTRs, this preliminary study was undertaken to investigate the anti-SARS-CoV-2 antibody response after the first injection. The protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013–1990).

We examined 242 KTR who received the first injection of the Moderna mRNA-1273 vaccine (100 μ g) at the Strasbourg University Hospital (France) between January 21 and 28, 2021. All had a negative history for COVID-19 and tested negative for anti-SARS-CoV-2 antibodies on the day of the first injection. The anti-SARS-CoV-2 antibody response was assessed at 28 days post-injection using the ARCHITECT IgG II Quant test (Abbott, Abbott Park, IL, USA), with titers >50 AU/mL being considered as positive.

One patient developed mild symptomatic COVID-19 seven days after injection and only 26 (10.8%) KTRs had a positive serology at 28 days post-injection. The median IgG titer was 224 AU/mL (interquartile range: 76–496 AU/mL). Patients who seroconverted had longer time from transplantation, received less immunosuppression, and had a better kidney function (Table 1).

In summary, the burden of immunosuppression may induce a weak anti-SARS-CoV-2 antibody response in KTRs after the first injection of an mRNA COVID-19 vaccine. This finding is strikingly different compared with immunocompetent subjects – who invariably seroconverted after the first injection.^{3,4} We highlight the need not to delay the second vaccine injection in immunocompromised patients. Close surveillance is also recommended to discuss the opportunity of a third dose in less responsive patients. medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252741; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

- COVID-19 Vaccination Program Operational Guidance | CDC. https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html. Accessed March 1st, 2021.
- 2. ECDC. https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccinationand-prioritisation-strategies.pdf. Accessed March 1st, 2021.
- 3. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *N Engl J Med*. 2020;383(20):1920-1931.
- 4. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *The Lancet*. 2021;0(0).

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252741; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 1 Characteristics of kidney transplant recipients according to serological response after

the first dose of the Moderna mRNA-1273 vaccine

	SARS-CoV-2			
Entire cohort	seronegative patients	SARS-CoV 2 seropositive		Missing
	57.7 (49.6-			
57.7 (49.3-67.6)	67.7)	58.4 (43.366.9)	0.51	0
156 (64.7%)	142 (66.1%) 25 7 (22 8-	14 (53.9%)	0.28	0
25.7 (22.6-29.5)	29.4)	26.4 (21.9-29.9)	0.73	2
,				
6.4 (2.9-13)	5.8 (2.8-11.9)	15.4 (8.6-25.9)	< 0.001	2
202 (83.8%)	176 (81.8%)	26 (100%)	0.01	0
192 (79.6%)	172 (80%)	20 (76.9%)	0.8	0
			0.02	2
94 (39.3%)	82 (38.5%)	12 (46.2%)		
101 (42.3%)	93 (43.7%)	8 (30.8%)		
30 (12.6%)	29 (13.6%)	1 (3.9%)		
14 (5.9%)	9 (4.2%)	5 (19.2%)		
× ,			0.001	7
138 (59.5%)	127 (60.8%)	11 (47.8%)		9
88 (37.9%)	80 (38.3%)	8 (34.8%)		
6 (2.6%)	2 (1%)	4 (17.4%)		
			0.06	0
133 (55.2%)	124 (57.7%)	9 (34.6%)		
82 (34%)	69 (32.1%)	14(50%)		
26 (10.8%)	22 (10.2%)	4 (15.4%)		
191 (79.3%)	177 (82.3%)	14 (53.9%)	0.002	0
7 (2.9%)	4 (1.86%)	3 (11.5%)	0.03	0
35 (14.5%)	32 (14.9%)	3 (11.6%)	1	0
142 (58.9%)	133 (61.9%)	9 (34.6%)	0.01	0
9 (3.8%)	9 (4.2%)	0	0.26	0
. ,				
51.6 (38.1-68)	51 (37.9-66.5)	64.9 (39.9-72.2)	0.08	0
118 (99-158)	120 (101-159)	104 (85-134)	0.05	0
	Entire cohort (n=241*) 57.7 (49.3-67.6) 156 (64.7%) 25.7 (22.6-29.5) 6.4 (2.9-13) 202 (83.8%) 192 (79.6%) 94 (39.3%) 101 (42.3%) 30 (12.6%) 14 (5.9%) 138 (59.5%) 88 (37.9%) 6 (2.6%) 133 (55.2%) 82 (34%) 26 (10.8%) 191 (79.3%) 7 (2.9%) 35 (14.5%) 142 (58.9%) 9 (3.8%) 51.6 (38.1-68) 118 (99-158)	SARS-CoV-2 seronegative patients $(n=241*)$ SARS-CoV-2 seronegative patients $(n=215)$ 57.7 (49.3-67.6) 156 (64.7%)57.7 (49.6- 67.7)156 (64.7%)142 (66.1%) 25.7 (22.8- 25.7 (22.6-29.5)25.7 (22.6-29.5)29.4)6.4 (2.9-13) 202 (83.8%)5.8 (2.8-11.9) 176 (81.8%) 172 (80%)94 (39.3%) 192 (79.6%)82 (38.5%) 101 (42.3%) 93 (43.7%) 30 (12.6%)94 (39.3%) 101 (42.3%) 30 (12.6%)82 (38.5%) 9 (4.2%)138 (59.5%) 14 (5.9%)127 (60.8%) 80 (38.3%) 6 (2.6%)133 (55.2%) 124 (57.7%) 82 (34%) 6 (32.1%) 26 (10.8%) 22 (10.2%)133 (55.2%) 191 (79.3%)124 (57.7%) 177 (82.3%) 7 (2.9%) 4 (1.86%) 35 (14.5%) 32 (14.9%) 142 (58.9%)138 (99-158)120 (101-159)	SARS-CoV-2 seronegative patientsSARS-CoV 2 seropositive patientsEntire cohort $(n=211^{\circ})$ SARS-CoV 2 seropositive patients $(n=26)$ 57.7 (49.3-67.6)67.7)58.4 (43.366.9) 142 (66.1%)14 (53.9%) 25.7 (22.8- 25.7 (22.6-29.5)25.7 (22.6-29.5)29.4)26.4 (21.9-29.9)6.4 (2.9-13)5.8 (2.8-11.9)15.4 (8.6-25.9) 202 (83.8%)176 (81.8%) 26 (100%)192 (79.6%)172 (80%)20 (76.9%)94 (39.3%)82 (38.5%)12 (46.2%) 8 (30.8%)101 (42.3%) 30 (12.6%)29 (13.6%)1 (3.9%) 1 (3.9%)14 (5.9%)9 (4.2%)5 (19.2%)138 (59.5%)127 (60.8%)11 (47.8%) 8 (34.8%) 6 (2.6%)133 (55.2%)124 (57.7%) 2 (1%)9 (34.6%) 14 (50%) 2 6 (10.8%)133 (55.2%)124 (57.7%) 3 (11.6%)133 (55.2%)124 (57.7%) 3 (11.5%)35 (14.5%)32 (14.9%)35 (14.5%)32 (14.9%)35 (14.5%)32 (14.9%)35 (14.5%)32 (14.9%)35 (14.5%)32 (14.9%)35 (14.5%)32 (14.9%)35 (14.5%)32 (14.9%)9 (33.8%)9 (4.2%)051.6 (38.1-68)51 (37.9-66.5)64.9 (39.9-72.2)118 (99-158)120 (101-159)104 (85-134)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

*The patient who developed COVID-19 after the first injection was excluded from the analysis.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252741; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Continuous variables are presented as medians (interquartile ranges), whereas categorical variables are presented as counts (percentages).

Abbreviations: BMI, body mass index; CNI, calcineurin inhibitors; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid